Discussion
Cutaneous vasculitis (CV) is defined as an inflammatory disorder
affecting the small vessels of the dermis. Clinical manifestations are
urticarial, papules, plaques, palpable purpura, ulcers, nodules and
livedo. Cutaneous vasculitis is classified based on the type of
inflammatory infiltrations on the biopsy specimen, and the size of the
involved vessels, etc. The most important subtypes are neutrophilic
vasculitis, lymphocytic vasculitis, necrotizing vasculitis, thrombosing
vasculitis, eosinophilic vasculitis, and granulomatous vasculitis. CV
could be part of a systemic vasculitis or occur separately and be
self-limited. The most common etiologies are infections, autoimmune
systemic disorders, malignancies, drugs, and vaccines. CV represents a
self-limited course in most cases. Systemic corticosteroids and
immunosuppressive agents might be required in severe and systemic
diseases [1]. Different types of vasculitis have been reported as
adverse events following immunization. Culprit vaccines are influenza,
BCG, human papillomavirus, and hepatitis B vaccines [2]. CV has been
associated with both Coronavirus disease-2019 (COVID-19), and SARS-CoV-2
vaccines [3, 4]. The inflammatory response triggered by the vaccine,
and immune complex deposition within the vessels wall of the dermis have
been described as the cause of this adverse event. The responsible
antigen for such an immune reaction might be the vaccine component
encoding SARS-CoV-2 spike glycoprotein [5]. In conclusion, LCV could
be a possible adverse event of different SARS-CoV-2 vaccines. Clinicians
and manufacturers should be aware of this adverse event.